Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has received notification that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,746,088, which covers composition of matter for deuterated tryptamine compounds and pharmaceutical composition; the grant provides exclusivity … Continue reading InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notification of Approval for U.S. Patent Covering Deuterated Tryptamines